Expert in nanoparticle synthesis and cancer cell analysis with a focus on live tracking drug delivery systems. Skilled in using in-vitro cell models and molecular signaling techniques to target cancer cells. Proven ability to collaborate with multidisciplinary teams to develop solutions for drug-resistant cancer. Adept at translating complex data into actionable insights for research and clinical use.
Undergraduate Mini-Project, 2019, 6 months, The New College, Amylase enzyme production in fungi was studied by isolating and identifying species. The production of amylase was quantified, and both batch and continuous fermentation methods were used to determine the yield. Postgraduate Project, 2021, 6 months, SRM Institute of Science and Technology, In silico analysis was conducted to identify the heterogeneity of gene expression in rheumatoid arthritis patients. This analysis confirmed the homology with gene regions in individuals and was validated through primer design, validation, and electronic quantitative PCR. Doctor of Philosophy, 2025, 48 months, SRM Institute of Science and Technology, I developed cancer cell lines that are resistant to doxorubicin and studied their characteristics through targeted gene and protein analysis. This included techniques such as quantitative PCR, immunohistochemistry, flow cytometry, ELISA, and immunoblotting. Additionally, I synthesized honeycomb-structured nanoparticles that were loaded with various therapeutic agents, including fluorescent markers, adjuvants, and chemotherapy drugs, to specifically target and inhibit the resistant cancer cells. The cytotoxicity of these treatments was evaluated by comparing their effects on primary healthy cells with those on the cancer-resistant cells.
I declare that the information furnished above matches my knowledge and belief.
Targeted co-delivery system to resistant cancer cells